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A B S T R A C T
Stroke is an acute insult to the central nervous system (CNS) that triggers a sequence of responses in the acute,
subacute as well as later stages, with prominent involvement of astrocytes. Astrocyte activation and reactive
gliosis in the acute stage of stroke limit the tissue damage and contribute to the restoration of homeostasis.
Astrocytes also control many aspects of neural plasticity that is the basis for functional recovery. Here, we
discuss the concept of intermediate filaments (nanofilaments) and the complement system as two handles on the
astrocyte responses to injury that both present attractive opportunities for novel treatment strategies modulating
astrocyte functions and reactive gliosis.
1. Introduction
Stroke is the second most common cause of death globally after
coronary heart disease [1,2]. One in 6 persons will experience a stroke
during his/her life and 1 in 10 will die of it [1,2]. The majority of stroke
survivors live with serious disabilities requiring long-term assistance.
Stroke care alone absorbs 5–6% of all health expenditures making it
extremely expensive [3]. Despite the magnitude of the problem, there
are only very few effective treatments for stroke. Stroke is a highly
heterogeneous disease (ischemic stroke i.e. brain infarction, in-
tracerebral and subarachnoidal hemorrhage being the major subtypes,
each with several distinct causes and risk factors; Fig. 1). Ischemic
stroke occurs when a cerebral artery is occluded by a blood clot that is
formed locally (thrombus) but more often comes from another location
(embolus, e.g. from the heart or from an atherosclerotic plaque in a
large proximal artery). If this occlusion is not rapidly reversed, an is-
chemic infarct develops due to the insufficient supply of oxygen and
nutrients to the affected tissue. Intracerebral hemorrhage is caused by
rupture of a cerebral artery wall and bleeding into the brain
parenchyma, resulting in brain edema, brain injury and neuroin-
flammation. Subarachnoidal hemorrhage is caused by rupture of a
cerebral artery aneurysm and bleeding into the subarachnoidal space.
While ischemic stroke is most common (75–80% of all strokes), he-
morrhagic stroke is associated with high (about 50%) mortality rate
[4].
Several effective acute treatments for ischemic stroke emerged
during the last decades (e.g. stroke unit care, intravenous thrombolysis,
thrombectomy, or decompressive craniectomy). For subarachnoidal
hemorrhage, the only effective treatment is the closure of the aneurysm
after which the risk of re-bleeding is very low. Several trials with sur-
gical interventions or drugs have failed to show clinical benefit (for a
review: see [5]) and apart from supportive measures [6–8] no effective
treatment exists for intracerebral hemorrhage.
Loss of function after stroke is due to both cell death in the directly
damaged tissue and cell dysfunction in the surrounding as well as re-
mote brain areas that are connected to the damaged area. Recovery of
function involves reversal of dysfunction, activation of cell repair,
functional reorganization within existing networks (changing the
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properties of existing neural pathways) and neuroanatomical plasticity
leading to the formation of new connections through axonal sprouting
and synaptogenesis [8,9]. There is a mounting body of evidence to
support the critical role of reactive astrocytes in the responses of the
brain parenchyma to stroke [10–12]. In the acute phase, astrocytes
limit the tissue damage and contribute to the restoration of
Fig. 1. Stroke is caused by either an occlusion (ischemic stroke) or rupture (hemorrhagic stroke) of a blood vessel supplying the brain with oxygen and
nutrients. A–C, ischemic stroke. A, An illustration of a distal middle cerebral artery occlusion on the left side with a blood clot, leading to ischemic changes and
eventually cerebral infarction. B, Human brain autopsy showing a wedge-shaped acute infarct in the middle cerebral artery territory. C, A computer tomography (CT)
image of an acute infarction in the whole middle cerebral artery territory with an expansion and a midline shift. D–F, hemorrhagic stroke. D, An illustration of a deep
penetrating artery rupture leading to intracerebral hematoma with surrounding edema (depicted in blue). E, Intracerebral hemorrhage in the right hemisphere of
human brain autopsied a few days after the event. F, CT of a typical intracerebral hemorrhage.
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homeostasis. Given that in the post-acute and chronic phase, astrocytes
seem to both facilitate and inhibit neural plasticity processes that form
the basis for functional recovery, modulation of astrocyte function at
this later stage appears as an interesting approach to improve the long-
term outcome for stroke survivors.
2. Astrocytes and reactive gliosis
Astrocytes control many functional aspects of CNS in health and
disease, including the maintenance of the CNS homeostasis, control and
support of neurons, neurotransmitter recycling, control of blood flow
and the induction, functional control and removal of neuronal synapses
[13–20]. The highly complex bush-like morphology with thousands of
fine cellular processes, induced by interactions between astrocytic
neuroligins and neuronal neurexins [20], enables the astrocyte to be in
contact with neuronal synapses and form end-feet wrapping around
blood capillaries as a key component of the blood brain barrier [21–23]
(Fig. 2A).
In response to the physiological changes in the CNS homeostasis as
well as in pathological situations, astrocytes become activated and this
activation has both general and disease-specific characteristics
[12,24,25]. In a cross-talk with microglia, astrocytes are key players in
the acute and sub-acute tissue responses to injury in a response known
as reactive gliosis, a term used for the activation of astroglial cells re-
gardless of the inducing event [11,24,26,27]. Reactive astrocytes are
characterized by hypertrophy of their cellular processes and show al-
tered expression of many genes including the up-regulation of glial fi-
brillary acidic protein (GFAP), the main component of astrocyte cyto-
plasmic intermediate filaments (aka nanofilaments) (Fig. 2B). Astrocyte
cytoplasmic nanofilaments are composed of GFAP, vimentin, in some
cases also nestin and synemin [28–31], and are highly dynamic struc-
tures involved in cell signaling, cell migration, determine cellular vis-
coelastic properties in reactive glia [32] and they act as a signaling
platform that controls cell stress responses, both in health and disease
[29,33–36]. In their latter role, they can be viewed as a crisis command
center of cells, and this function of cytoplasmic nanofilaments extends
to many other cell types [24,37].
Reactive astrogliosis is a graded reaction [25,35], the most severe
form being a glial scar that involves also microglia or pericytes
[32,38,39]. Gene expression data showed that astrogliosis has both
general and disease-specific components and astrocytes within the same
tissue exhibit substantial heterogeneity [40].
Despite the hypertrophy of their cellular processes, reactive astro-
cytes in acute neurotrauma stay within their tiled domains with a
Fig. 2. Astrocytes occupy distinct domains within the brain parenchyma
and interact extensively with each other (forming a network, syncytium),
with neuronal synapses and blood capillaries. In response to an injury,
astrocytes get activated and their cellular processes become hypertrophic,
however reactive astrocytes remain within their tiled domains. Reactive
astrocytes surrounding the lesion area (e.g. ischemic stroke lesion) show
characteristic upregulation of intermediate filament (nanofilament) pro-
teins GFAP or nestin. Gene expression profiling of individual astrocytes
shows remarkable heterogeneity of astrocytes, which becomes even more
prominent within the population of astrocytes responding to an injury. A,
Three-dimensional reconstruction of a dye-filled astrocyte in the dentate gyrus
of the hippocampus of a mouse reveals fine astrocyte processes including those
forming the astrocyte end-feet (arrowheads) that wrap around a capillary (note
that no specific visualization of the capillary itself has been used here). For 3D
reconstruction done for this image, see [84]. B, Four days after photo-
thrombotic stroke lesion in the mouse cortex, reactive astrocytes within wide
area around the lesion overexpress GFAP, while astrocytes directly adjacent to
the lesion also express nestin. Some astrocytes characteristically extend their
processes towards the lesion (arrows); picture provided by Pekny's laboratory
(Drs. R. Leke and U. Wilhelmsson). C, In response to injury, the main astrocyte
processes get thicker and visible over a greater distance (compare the circles
and their radii), but the astrocyte domains do not get larger [41]. D, Quanti-
fication of mRNA in individual astrocytes directly isolated from uninjured
hippocampus or from hippocampus of mice 4 days after unilateral enthorhinal
cortex lesion shows that a difference between low and high GFAP expressing
astrocytes can be>30-fold in uninjured situation, and>3000 fold in astrocyte
populations that contain reactive astrocytes [82]. Green, GFAP; purple, nestin
in C. Scale bar 10 and 100 μm in A and B, respectively.
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similar extent of a minimal overlap between the adjacent astrocyte
territories as seen in naïve astrocytes [41] (Fig. 2C). This is in contrast
to the lost organization of astrocyte domains in animal models of epi-
lepsy, which might reflect pathological remodeling and, interestingly,
can be partially normalized by some antiepileptic drugs, e.g. valproate
[42]. Aging adds additional component to this picture. On one hand,
reactive gliosis, at least in some parts of the CNS, tends to increase with
age [43–45], as does the territorial volume of astrocytes in a mouse
neocortex and hippocampus [46]. On the other hand, some astrocytes
exhibit signs of regional atrophy and functional asthenia both in the
aging CNS and in some neurological diseases [47,48]. Thus, the astro-
cyte domain principle seems to be an important feature of astrocyte
function, and when disturbed, may trigger or contribute to disease
pathogenesis.
3. Astrocyte responses in stroke and the astrocyte nanofilament
system
Within hours after stroke, astrocytes respond to hypoxia, neuronal
cell death, release of neurotransmitters, and blood extravasation by
altered expression of many genes, including those involved in STAT
signaling [49,50]. The JAK/STAT3 signaling pathway is the main
switch controlling a number of molecular and functional changes in
reactive astrocytes. A number of signaling molecules, e.g. transforming
growth factor (TGF)-alpha, ciliary neurotrophic factor (CNTF), inter-
leukin (IL)-6, leukaemia inhibitory factor (LIF), or oncostatin M are
known to trigger astrocyte activation [51–56]. These signaling events
lead to upregulation of GFAP, vimentin and nestin, changes in cell
morphology and cell proliferation [35,57]. Within days, astrocytes in
the stroke penumbra proliferate and some migrate towards the infarct
boarder to form a glial scar by secreting extracellular matrix (ECM)
molecules. This helps to restrict the area of damage and to prevent
infiltrating leukocytes from invading the healthy tissue [58,59]. Some
astrocytes within the reactive boarder show a polarized morphology
while astrocytes further away from the infarct show a stellate mor-
phology (Fig. 2B).
Both ischemic and hemorrhagic stroke lead to brain edema, which
can become a life-threatening condition. In cytotoxic brain edema, the
lack of oxygen and glucose results in malfunction of the sodium and
potassium pump in the astrocyte membrane leading to rapid swelling of
the cell. The unique ability of astrocytes to respond to hypoosmotic
environment by transient swelling and their tendency to assume their
original cell volume [60] is called a regulatory volume decrease and
involves an efflux of osmotically active molecules, e.g. taurine from
astrocytes [61–63]. Regulatory volume decrease by astrocytes is a key
mechanism in counteracting the development of brain edema due to
ischemia or trauma, conceivably with cytoskeleton‐linked stretch‐-
activated plasma membrane channels acting as cell‐volume sensors
[64–67]. Indeed, intermediate-filament-fee astrocytes subjected to hy-
poosmotic stress exhibit about 50% reduction in taurine release com-
pared to wild‐type astrocytes [68]. In contrast, vasogenic edema is
caused by rupture of a vessel and leads to a disruption of the blood
brain barrier (BBB) and a direct entry of both blood cells and plasma
into the extravascular space of the brain.
Astrocytes associate with, and control the function of the deep pe-
netrating blood vessels, along which cerebrospinal and interstitial fluids
are exchanged. Due to its resemblance with the lymphatic system, the
term glymphatic system has been coined for this structural and func-
tional arrangement [69,70]. The cerebrospinal fluid enters and the in-
terstitial fluid leaves the brain parenchyma through the astrocyte vas-
cular end-feet, and astrocyte Aquaporin-4 (AQP4) channels facilitate
this process. The positioning of AQP4 channels in the astrocyte mem-
brane is highly polarized towards the vascular end-feet and mice defi-
cient in AQP4 show greatly reduced glymphatic clearance of solutes
[69]. Water transport and the glymphatic brain homeostasis are highly
disturbed after stroke due to the loss of APQ4 polarization in the cell
membrane of reactive astrocytes [71] and mice deficient in AQP4 ex-
hibit impaired ability to counteract vasogenic edema [72] On the other
hand, other studies showed that AQP4 deletion reduced brain edema
after ischemic stroke [73,74]. This suggests that the bi-directional
water transport facilitated by AQP4 may be beneficial or detrimental
depending on the edema type, i.e. AQP4-facilitated water transport may
contribute to astrocyte swelling in the acute phase after stroke but may
inhibit astrocyte uptake of extracellular fluid at a later stage.
Reactive astrocytes are thought to play a major role in the post-
stroke functional recovery. Reactive astrocytes in the periinfarct cortex
inhibit axonal sprouting through, for example, up-regulation of the
inhibitory signaling ligand Ephrin-A5 as the inhibition of ephrin-A5
after stroke promoted axonal outgrowth and functional recovery [75].
Reactive astrocytes may also inhibit the post-stroke synaptic plasticity
that allows re-mapping of lost functions within the damaged tissue
through an impaired function of the astrocyte GABA (γ-aminobutyric
acid) transporter GAT-3 in the periinfarct area, resulting in increased
tonic neuronal inhibition. This inhibition can be abrogated by experi-
mental treatment with specific agonist for α5-subunit-containing ex-
trasynaptic GABA(A) receptors an thus provides a novel treatment
strategy to promote functional recovery after stroke [76]. On the other
hand, astrocyte secretion of synaptogenic thrombospondins 1 and 2
(Thbs-1/2) was increased in the penumbra of ischemic stroke in mice
[15], and genetic deletion of Thbs-1/2 impaired post-stroke synapto-
genesis [77]. The role of other astrocyte-derived regulators of synapse
number and function, such as SPARC, Hevin, glypicans 4 and 6, Megf10
and MERTK [18,19,78] in post-stroke recovery is currently unknown, as
is the functional contribution to the new neurons generated from
striatal astrocytes [79].
Transcriptome-wide analysis of astrocyte gene expression facilitates
the understanding of the disease-specific astrocyte responses. Thus, the
set of genes affected in the ischemic stroke and bacterial endotoxin-
induced neuroinflammation models was partially overlapping and
partially unique to the respective pathology, with additional differences
seen in the temporal expression pattern [80]. The possibility to assess
the gene transcription on a single cell level provides unique information
about the heterogeneity within the astrocyte population and forms the
basis for astrocyte sub-classification.
Gene profiling of individual astrocytes in primary cultures and as-
trocytes in vivo revealed the diversity in expression levels in individual
astrocytes and points to the existence of distinct astrocyte subpopula-
tions [81,82]. For example, in the healthy hippocampus of an adult
mouse, there is a 30-fold range in number of Gfap mRNA copies be-
tween individual astrocytes, but in the injured hippocampus this range
increases to more than 3000-fold (Fig. 2D). We have recently identified
a subpopulation of cells expressing both astrocyte and microglia-spe-
cific genes (Fig. 3). These cells with dual astrocyte/microglia molecular
identity (M/A cells) are absent in the healthy mouse or human brain,
but were found both in the injured mouse hippocampus and in the
brains of stroke or Alzheimer’s disease patients [82]. The function of
these subpopulations of reactive astrocytes remains to be identified.
One approach to look into the function of reactive astrocytes in
stroke and other neurological diseases is genetic ablation of astrocyte
intermediate filament proteins, specifically GFAP and vimentin. The
simultaneous absence of GFAP and vimentin in GFAP−/−Vim−/− mice
results in intermediate filament-free reactive astrocytes [83] that are
present in normal numbers and form normally tiled domains [84], but
upon injury, do not develop the characteristic hypertrophy of their
main cellular processes [41,84] and show other signs of attenuated
reactive gliosis, e.g. decreased activation of Erk and c-fos [85] or less
prominent upregulation of the 14-3-3 adapter proteins [86]. At the
acute stage after neurotrauma, GFAP−/−Vim−/− mice show slower
healing and increased synaptic loss [83,84], decreased resistance of the
neural tissue to mechanical stress [87,88], and in situations connected
with neurodegeneration (Alzheimer’s or Batten disease), increased
neuronal damage [89,90].
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Ischemic stroke induced in GFAP−/−Vim−/− mice by middle cere-
bral artery transection results in larger infarcts, with GFAP−/−Vim−/−
astrocytes showing less efficient endothelin-3-induced blockage of gap
junctional communication [10], decreased glutamine levels [91], lower
total and GLT-1-mediated glutamate transport [10] and impaired re-
sponse to oxidative stress [92], demonstrating that astrocyte inter-
mediate filaments are required for the neuroprotective function of as-
trocytes at the acute stage of ischemic stroke. Similarly, GFAP−/
−Vim−/− mice exhibit lower cell survival in the inner retina after
retinal ischemia-reperfusion [93]. Interestingly, the very same genetic
attenuation of reactive gliosis does not affect the infarct volume in mice
subjected to a photothrombotic brain injury [94], an ischemic injury
model with a very limited or no ischemic penumbra [95], or tissue loss
after neonatal hypoxic-ischemic brain injury [96], a model of birth
asphyxia. These findings show that the intermediate filaments play a
positive role in responses of astrocytes to various acute stresses. How-
ever, they also suggest that the protective effect of reactive gliosis at the
acute stage after injury depends on the lesion type and may differ be-
tween developing and adult brain.
On the other hand, a number of negative effects of reactive gliosis
have been documented and several disease models show that reactive
gliosis may become detrimental at the later stage after injury [24,97].
Thus, the inhibition of chondroitin sulphate proteoglycans produced by
astrocytes and oligodendrocyte precursors, can improve post-traumatic
axonal regeneration [98–103], or ephrin-A5 produced by reactive as-
trocytes is known to limit axonal sprouting and functional recovery
after injury [75]. Apart from its downsides at the acute stages of injury,
attenuation of reactive astrogliosis in GFAP−/−Vim−/− mice gives
several desirable outcomes, such as better synaptic regeneration [84],
better regeneration and functional recovery after spinal cord injury
[104], or better regeneration of the severed optic nerve in postnatal
mice [105].
Astrocytes are known to control differentiation of neural stem cells
by a variety of mechanisms - via secreted factors [106–108],
Fig. 3. Single cell gene expression profiling allows the identification of subpopulations of astrocytes, including those specific for particular disease
situations. Thus, a distinct subpopulation of GFAP positive cells was found that also express makers of microglia, such as Cx3cr1, Cd68, Itgam or Aif1,
showing that some cells have molecular characteristics of both astrocytes and microglia [82]. These dual identity cells (M/A cells) can be found only after
experimental injury but not in naïve brains, and they were also identified in the brains of stroke and Alzheimer’s disease patients [82]. A, Scatter plots showing a
subpopulation of cells expressing both microglia marker Cx3cr1 and astrocyte marker Gfap in the injured mouse hippocampus. B, M/A cells positive for both
astrocyte-specific (GFAP and Aldh1l1) and microglia-specific (Tmem119) proteins are present in the brain of stroke patients but not of healthy individuals [82].
Arrowheads, M/A cell; A, astrocyte; M, microglia. Scale bars, 10 μm.
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membrane-associated molecules [109], as well as through direct cell-
cell interactions [110]. In the adult rodent hippocampus, the newly
born neurons get integrated into the existing neural circuitry
[111–114], and this facilitates both the formation of new memories
[115] and forgetting of the previously acquired and stored information
[116]. This has important implications for both the healthy and injured
brain. Interestingly, both basal [45,117], adult post-traumatic [117],
and neonatal post-hypoxic/ischemic [96] hippocampal neurogenesis
are increased in GFAP–/–Vim–/– mice, and we proposed that the negative
control of neurogenesis by astrocytes via Notch signaling to neural stem
cells [117,118], and intracellular vesicle trafficking in astrocytes
[119–121], depend on GFAP and vimentin. In addition, the CNS niche
of GFAP−/−Vim−/− mice supports better differentiation, integration
and survival of neural grafts [122] and better neuronal and astrocyte
differentiation of transplanted adult neural stem cells [123]. To what
extent this results from attenuated reactive gliosis or from altered in-
teractions between host astrocytes and the grafted cells remains to be
established.
Thus, the positive roles of reactive gliosis at the acute phase of
neurotrauma or ischemic injury, may, at least in some situations be
counteracted by restricted regenerative potential at later stages. This
opens a window of therapeutic opportunities. Can we pharmacologi-
cally target astrocyte intermediate filaments with the aim of improving
outcome after brain injury or stroke? Some in vitro data already point
in that direction, e.g. epoxomycin, a proteasome inhibitor, which de-
creases the GFAP levels in astrocytes [124], when applied to astrocyte-
neuron co-cultures exposed to ischemia, increases the survival of neu-
rons without compromising the ability of astrocytes to cope with is-
chemic stress [125]. These data hold promise for future stroke thera-
pies, however, the effect of treatment with epoxomycin and other
compounds that affect the expression and function of intermediate fi-
lament proteins in astrocytes on functional recovery after experimental
stroke remains to be investigated.
4. Complement: a modulator of astrocyte response to injury
Over the past decade, the complement system emerged as a critical
regulator of astrocyte function, not least in the post-stroke brain.
Complement is a major effector of the innate immune response.
However, there is a growing body of evidence that besides its role as a
first line of defense against invading pathogens, complement fulfills
also a range of functions that have direct implications for normal brain
development and function, and the response of brain cells to injury.
Complement consists of a group of over 50 circulating and cell mem-
brane-bound proteins. Although liver is the source of the majority of the
circulating complement proteins, most complement proteins, soluble
molecules and receptors alike, are also produced locally in the CNS.
Here, we will focus on the astrocyte-related actions of three comple-
ment proteins, namely C1q, C3 and C5.
C1q is a subunit of the C1 complex and a pattern recognition mo-
lecule of the classical pathway of complement activation. C1q binds
antigen-bound antibodies and a range of pathogen-associated mole-
cules, but also C-reactive protein, pentraxin-3, beta-amyloid fibrils,
DNA, mitochondrial membranes and a variety of molecules exposed by
apoptotic and necrotic cells (reviewed in [126]). C1q-ligand binding
leads to a sequence of proteolytic activation steps and subsequent
proteolytic activation of C3 that generates two fragments: smaller C3a
that is released and larger C3b that binds to the activating target
structure. C3a exerts it functions through C3a receptor (C3aR) whereas
C3b and its derivatives, are recognized by complement receptors (CR)
1–4 on phagocytic cells and B-cells. C3b is also a component of the C3
and C5 convertase complex that proteolytically activates C3 and C5.
Similar to C3, C5 activation liberates a small C5a fragment that binds to
C5a receptors (C5aR1 and C5aR2), and C5b that binds to the activating
target and participates in the activation of the terminal part of the
complement cascade.
Astrocytes express Megf10, a scavenger receptor that binds C1q
[127]. Astrocytes express also C3aR [128–130], C5aR1 [131–133],
C5aR2 [134], CR3 [135]. In addition, human astrocytes were reported
to express also CR1 and CR2 [136,137].
Astrocytes respond to focal brain ischemia by profound changes in
gene expression [80]. It has been recently proposed that endotoxin
triggered neuroinflammation, acute CNS trauma or normal aging in-
duce a neurotoxic astrocyte phenotype [80,138,139] whereas astro-
cytes in the post-ischemic brain were suggested to be neuroprotective
[80,139]. Microglia-astrocyte interaction appears to play a critical role
in determining the reactive astrocyte phenotype. Microglia-derived
cytokines such as TNF-alpha, IL-1beta and IL-6 were shown to trans-
form astrocytes into neuroprotective phenotype after brain trauma
[140]. C1q secreted by microglia in response to LPS has been put for-
ward as one of the signaling molecules needed for the induction of
neurotoxic astrocytes [139]. However, it is not known which astrocyte
receptor is needed for C1q to exhibit this effect. As binding of C1q to
Megf10 is required for normal clearance of apoptotic cells [127],
Megf10, which is predominantly expressed by astrocytes [135], is
clearly a possible candidate. Microglial expression of C1q is also in-
creased with age [141], as is the astrocyte expression of Megf10 and
CR3, and to a lesser degree C3 [138]. Megf10 is critical for neuronal
activity dependent synapse remodelling by astrocytes [78]. In the de-
veloping CNS, astrocytes instruct neurons to tag weak synapses with
C1q [142] to trigger the activation of the classical complement
pathway, a process leading to synapse elimination via the C3b-micro-
glial CR3 interaction [143,144]. The C1q and CR3-dependent phago-
cytosis is also of critical importance for neurodegenerative post-injury
debris clearance by microglia [145].
The specific involvement of the classical pathway activation-in-
dependent C1q-Megf10 interaction in the regulation of synapse number
in the developing, diseased and aging brain remains to be investigated.
C1q deficiency protected neonatal mice against hypoxic-ischemic brain
injury [146]. In the developing brain subjected to hypoxia–ischemia,
C1q accumulates in neuronal cytosol and accelerates mitochondrial
production of reactive oxygen species that in turn potentiate oxidative
injury [147]. Adult mice deficient in C1q were not protected against
acute tissue loss after ischemic stroke or hypoxic-ischemic brain injury
[147–149]. C1q is pro-angiogenic [150], neuroprotective, and stimu-
lates neurite outgrowth in vitro and axon regeneration in vivo
[151,152]. Thus, C1q exhibits its effects on both neurons and astro-
cytes, these actions are under strict developmental regulation, and at
least some of them are independent of complement activation.
Somewhat surprisingly, C3 was recently put forward as a marker of
neurotoxic astrocytes [139], despite its absence among the top 50 genes
up-regulated in LPS induced astrocytes and its up-regulation by
ischemia induced astrocytes [80]. Activation of NFkappaB in astrocytes
leading to secretion of C3 and subsequent excessive activation of neu-
ronal C3aR in the context of Alzheimer’s disease pathology impair
dendritic morphology and synaptic function [153]. These findings, to-
gether with the involvement of C3b in the loss of synapses indeed point
to the role of astrocyte derived C3 in neurodegeneration induced by
beta amyloid. In contrast, up-regulation of C3 in astrocytes seems to be
protective from early neuronal damage and loss in glaucoma [154], a
condition in which C1q plays a deleterious role [155]. Thus, at least in
some neurodegenerative conditions, C1q and C3 may play independent
roles. The specific involvement of astrocytes, C1q and C3 in different
disease context, including secondary neurodegeneration after stroke,
warrant investigation.
In transient focal cerebral ischemia, C3 deficient and C3aR an-
tagonist pre-treated mice showed reduced infarct volume and lesser
neurological impairment 24 h – 7 days after ischemia, conceivably due
to decreased granulocyte infiltration and reduced oxidative stress
[149,156], as C3a plays a critical role in endothelial activation and
leukocyte recruitment into the brain [157]. Similarly, treatment with
C3aR antagonist improved neurologic outcome, conceivably by
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reducing inflammatory cell infiltration and brain edema formation after
experimental intracerebral hemorrhage [158]. These results point to
the deleterious effects of C3aR signaling and therapeutic benefit of
systemic inhibition of C3aR signaling in the acute phase after stroke.
There is, however, also a growing body of evidence supporting the
beneficial role of C3 and C3aR signaling in the ischemic brain and a
potential neuroprotective role of astrocytes in this context. Ischemia
leads to the up-regulation of astrocyte C3aR [130,159,160]. Astrocytes
respond to C3a by changes in intracellular signaling [132] and the
expression of cytokines such as interleukin (IL)-6, IL-8 and nerve
growth factor (NGF) [131,161,162]. C3a promotes astrocyte survival
after ischemia by inhibiting ERK signaling-mediated apoptotic pathway
and caspase-3 cleavage [130]. Astrocytes are required for the neuro-
protective effects of C3a in an excitotoxic environment [163]. C3a
modulates also the fate of neural stem cells. C3aR signaling stimulates
adult neurogenesis in mice and neuronal differentiation of mouse
neural stem cells [164,165], however, C3a in combination with C1q
induced astroglial differentiation and migration of human neural stem
cells [166]. C3/C3aR neuron-glia signaling was suggested to promote
synaptic plasticity [153] but the specific mechanisms leading to C3a
generation in the unchallenged healthy brain are not known.
In vivo studies provide further support for the beneficial effects of
C3a/C3aR after brain ischemia. Mice expressing C3a in reactive astro-
cytes were protected against brain tissue loss due to neonatal hypoxic-
ischemic brain injury and single dose intraventricular injection of C3a
ameliorated neonatal hypoxia-ischemia-induced memory impairment
in wild type mice but not in mice lacking C3aR [167]. Intranasal
treatment with C3a once daily for 3 days starting 1 h after hypoxia-
ischemia reduced injury-induced reactive gliosis in the hippocampus
and improved long-term cognitive function [168]. In adult mice sub-
jected to permanent focal cerebral ischemia, C3aR deficiency decreased
whereas C3a overexpression increased the number of newly born neu-
rons in the peri-infarct region [169], the density and size of glutama-
tergic pre-synaptic terminals, and presumably synapses, in the peri-in-
farct region as well as in the contralesional hemisphere, and the
expression of GAP43, marker of axonal sprouting and plasticity [170].
GAP-43 is also upregulated during reactive synaptogenesis [171,172]
and astrocyte-derived GAP-43 promotes neuronal survival and plasti-
city [173]. Daily intranasal treatment with C3a for 2–3 weeks led to
similar positive effects on neural plasticity as well as faster and sus-
tained functional recovery [170]. Collectively, these data provide
strong evidence for the stimulatory effects of C3aR signaling on neural
plasticity and recovery of function in the post-acute phase after is-
chemic injury to the adult brain. Given the profound differences be-
tween the immature and adult brain with regard to the role of C1q
[147], it is perhaps not surprising that also the response of brain cells to
C3a is strongly influenced by the developmental stage. While in the
adult brain signaling through neuronal C3aR modulates dendritic
morphology and the function of synapses [153], C3a may exert its ef-
fects also indirectly through glial C3aR and the balance between neu-
ronal and glial C3aR signaling may be developmentally regulated.
The finding that C5 deficiency had no effect on infarct volume after
ischemic stroke [149], points to no or negligible role of C5 in brain
tissue damage after ischemia. However, neurons in the CNS were
Fig. 4. Complement is a modulator of astrocyte response to injury: known and putative functions of the complement components C1q, C3 and C5 in the
CNS. Upon binding to a target structure, e.g. antigen-antibody complex or as yet unidentified synaptic component, C1q triggers activation of the classical pathway
leading to the proteolytic activation of C3, opsonization of the target with C3b, and release of C3a. Importantly, C1q exerts some of its functions also in the absence of
other complement proteins, e.g by direct interaction with astrocyte Megf10. C3a and C5a can be also liberated from their parental proteins through the action of
proteases other than C3- and C5-convertase, respectively, however, the exact mechanism of C3a and C5a generation in the CNS is unknown. Astrocyte-mediated
functions of C1q, C3 and C5 are shown in bold.
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reported to have the capability to generate C5a following ischemic
stress and mice lacking C5aR1 had significantly reduced infarct vo-
lumes and improved neurological score [174]. Pre-treatment with
C5aR1antagonist reduced infarct volume and improved neurological
function assessed 24 h after transient focal brain ischemia [175];
treatment with C5aR1 antagonist alone or in combination with C3aR
antagonist was neuroprotective in the acute phase after intracerebral
hemorrhage [176]. Thus, acute inhibition of C5aR1 signaling appears to
improve outcome after ischemic as well as hemorrhagic stroke. How-
ever, as C5a has been reported to regulate synaptic plasticity and
cognitive function is severely impaired in C5aR1 deficient mice [177],
prolonged C5aR1 inhibition may compromise long-term recovery. In-
deed, as shown for secondary pathology and recovery after spinal cord
injury, C5a/C5aR1 signaling contributes to tissue injury in the acute
period but is required for optimal protective and/or reparatory astro-
cyte responses and glial scar formation in the post-acute phase [178].
The functions of C5aR2 in the ischemic brain are unknown, however,
C5aR2 has been recently shown to convey neuroprotection in a model
of traumatic spinal cord injury [179]. As C5aR2 is expressed by astro-
cytes, neurons as well as microglia [134,135], the specific role of C5aR2
in these cell-types remains to be addressed.
Perhaps not so surprisingly, the role of C1q, C5 and C3 in the injured
brain is complex and their actions are not limited to a single cell type
(Fig. 4). As the effects of these proteins are highly context specific and
developmentally regulated, the role of C1q, C3 and C5, their source and
cellular as well as molecular mechanism of action need to be carefully
determined for every pathological condition per se. While acute and
short-term inhibition of C3aR and C5aR signaling seems to reduce brain
tissue loss after stroke, both C3a and C5a may be needed for optimal
neural plasticity and long-term functional recovery. Systemic route of
administration of C3aR and C5aR1 antagonists may be preferable in the
acute phase to robustly inhibit recruitment of inflammatory cells from
the circulation. However, to avoid any potential adverse effects of
systemic delivery of the agonists as well as to ensure their sufficient
levels in the parenchyma, local routes of administration are highly
desirable. Intranasal delivery of C3aR agonists seems to be an attractive
approach to improve functional recovery after neonatal hypoxic-is-
chemic brain injury and ischemic stroke [168, 170]. Optimal ther-
apeutic window and dose as well as the potential benefits of this type of
treatment for other types of brain injuries, including hemorrhagic
stroke, need to be determined by further preclinical and clinical studies.
5. Conclusions
The response of astrocytes to injury is a major determinant of the
outcome after stroke. In the acute phase, reactive astrocytes are neu-
roprotective, however, in the post-acute and chronic phase, they act as
both positive and negative regulators of neural plasticity, including
generation of new neurons, axonal sprouting, and control of synapse
number and function. Modulation of astrocyte function at this later
stage, enhancing the neural plasticity promoting functions and de-
creasing the ones that hamper recovery, might be an attractive strategy
to improve functional outcome. Astrocyte intermediate filament pro-
teins may represent the right target for this objective and the comple-
ment system may be at least one of the suitable bullets to hit it.
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